Tari Ao Whānui

I te 17 o Hūrae, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) kua whakaaetia mana e te NMPA te tono hokohoko mō te Trastuzumab Deruxtecan (Enhertu®) mō te maimoatanga raina tuarua o te mate pukupuku puku. Kei roto i tēnei tono...Pānuihia atu»

Nō nā tata nei, i panuitia e Ascentage Pharma kua whakaaetia e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) tana aukati whiriwhiri Bcl-2 hou (APG-2575) hei rongoā mō ngā tūroro pakeke e pāngia ana e te mate pukupuku toto toto mau tonu/te mate pukupuku toto toto iti (CLL/SLL)...Pānuihia atu»

Nō nā tata nei, i panuitia e GenFleet Therapeutics kua whakaaetia e te Pharmaceutical Administration Bureau (ISAF) o te Rohe Whakahaere Motuhake o Macau o Haina a Dupert®（fulzerasib, GFH925/IBI351）hei rongoā mō ngā tūroro e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kei roto ngā whakarerekētanga KRAS G12C...Pānuihia atu»

I te 30 o Hune, i whiwhi whakaaetanga ā-ture te aukati MET Vebreltinib i whakawhanakehia motuhaketia e Avistone mai i te National Medical Products Administration (NMPA) o Haina mō te maimoatanga o ngā tūroro he mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) kua whanake haere i te rohe, kua horapa rānei, kei roto ko te MET whakakaha...Pānuihia atu»

I te 30 o Hune, 2025, ka panuitia e HUTCHMED kua whakaaetia te Tono Rongoā Hou (NDA) mō te whakakotahitanga o te ORPATHYS (savolitinib) me te TAGRISSO (osimertinib) e te Whakahaere Hua Hauora ā-Motu o Haina (NMPA) mō te maimoatanga o ngā tūroro he mate pukupuku kua horapa ki te rohe, he mate pukupuku rānei kua horapa ki te toto...Pānuihia atu»

I te 30 o Hune, i panuitia e te paetukutuku mana o te National Medical Products Administration (NMPA) kua whakaaetia a Anlotinib, he rongoā hou Akomanga 1 i whakawhanakehia e Chia Tai Tianqing, mō tētahi tohu hou i Haina: te whakakotahitanga o te rongoā me te chemotherapy mō te maimoatanga raina tuatahi o ngā tūroro ...Pānuihia atu»

I te 26 o Hune, 2025, ka panuitia e CARsgen kua whakaaetia e te National Medical Products Administration (NMPA) o Haina te New Drug Application (NDA) mō te satricabtagene autoleucel (“satri-cel”, CT041) (he hua pūtau-T CAR autologous hei ārai i te pūmua Claudin18.2) hei rongoā mō Claudi...Pānuihia atu»

I te 19 o Hune, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) kua whakaarohia te werohanga LM-108 a Livzon Pharmaceutical kia whakaurua ki te tohu whakaora hou. Ko te whakakotahitanga o te werohanga paturopi monoclonal Kefeqibai (LM-1...Pānuihia atu»

I te 19 o Hune, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) kua whakaarohia te IBI343 a Innovent Biologics kia whakaurua ki roto i te kaupapa tohu whakaora hou, e whakaarohia ana mo te maimoatanga o te mate pukupuku kua horapa ki te rohe, te mate pukupuku kua horapa rānei...Pānuihia atu»

I te 6 o Hune, i whakaputaina e te hautaka hauora o te ao, te Journal of Hematology & Oncology, ngā hua o te rangahau wāhanga I/II (KL264-01/MK-2870-001) o te TROP2 ADC sacituzumab tirumotecan (sac-TMT) auaha hei rongoā kotahi mō ngā pukupuku totoka kua horapa, kāore e taea te tango, ā, he uaua ki te...Pānuihia atu»

I te 10 o Hune, i panuitia e te Center for Drug Assessment (CDE) o te National Medical Products Administration (NMPA) kua whakaarohia kia arotakehia te Trastuzumab Deruxtecan (T-DXd, DS-8201a) mō te maimoatanga o ngā tūroro pakeke e pangia ana e te mate puku HER2-pai kua horapa ki te rohe, kua horapa rānei...Pānuihia atu»

Nō nā tata nei, i panuitia e Merck & Co., Inc. (Merck) kua whakaaetia te pembrolizumab, te aukati PD-1, e te National Medical Products Administration (NMPA) o Haina, kia whakamahia ngātahitia me te lenvatinib me te transarterial chemoembolization (TACE) hei rongoā i ngā tūroro kāore i te tangohia te...Pānuihia atu»